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Summary
 
Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glu-
cocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimer-
izing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the
mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb micro-
tubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits
paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of
chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis.
The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear
factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by
binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphory-
late NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not
transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill
cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced
apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and pre-
venting FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phos-
phorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation,
FasL expression, and apoptosis can occur after Bcl-2 phosphorylation.
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inding of Fas ligand (FasL)
 
1
 
 or an anti-Fas antibody to
Fas (APO-1 or CD-95) causes apoptosis in Fas-bearing
cells. Fas is ubiquitously expressed in various cell types (1–3),
but the expression of FasL is much more restricted (4–7). Al-
though the expression of FasL was originally considered to
be restricted to activated T cells and NK cells, FasL has been
identified in other cell types, including Sertoli cells and
cells of the eye, liver, and kidney (8). The expression of
functional FasL by some tissues contributes to their immune-
privileged status by preventing the infiltration of inflamma-
tory leukocytes (9, 10). Recently, constitutive FasL expres-
sion has been detected on some tumor cells, indicating that
it may function to induce apoptosis in Fas-expressing im-
mune cells when they attempt to enter the tumor (11–14).
Moreover, it has been postulated that the Fas/FasL system
has an important role in the pathogenesis of many diseases
such as hepatitis, insulin-dependent diabetes, cancer, and
thyroiditis (Hashimoto’s disease) (15–21).
The antiapoptotic gene Bcl-2 protects cancer cells from
apoptosis induced by a variety of anticancer agents (22–25).
The precise mechanism by which Bcl-2 inhibits drug-
induced apoptosis is unknown. Mice in which wild-type
Bcl-2 was overexpressed documented extended cell sur-
vival rather than increased proliferation and led to an accu-
mulation of lymphocytes that eventually progressed to B
and T cell malignancy after subsequent genetic changes
(26–28). Loss of function studies that knocked out the Bcl-2
or Bcl-X
 
L
 
 death suppressors demonstrated the loss of cells
from selected lineages (29–31). Although hematopoietic
lineages appear to develop normally in the Bcl-2–deficient
mice, they are unable to maintain homeostasis of lympho-
cytes because of excess apoptotic loss of B and T cells. Micro-
tubule-stabilizing agents such as paclitaxel and docetaxel
and microtubule-disrupting drugs such as vincristine, vinblas-
tine, and colchicine have antimitotic and apoptosis-inducing
activity (24, 25, 32, 33). Recently, screening of a library of
phage-displayed peptides identified human Bcl-2 as a pacli-
taxel-binding protein (34). Paclitaxel induces Bcl-2 phos-
phorylation and apoptosis in human leukemic, breast, and
 
1
 
Abbreviations used in this paper: 
 
L, ligand; NFAT, nuclear factor of acti-
vated T lymphocytes; PI, propidium iodide. 
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prostate cancer cells (24, 25, 35), suggesting that phosphory-
lation of Bcl-2 may inhibit Bcl-2 function. The regulation
of Bcl-2 function by phosphorylation has been demon-
strated at the level of formation of Bcl-2–Bax hetero-
dimers. However, it is also possible that Bcl-2 exerts its bio-
logical effects in additional protein interactions distinct from
those with proapoptotic family members.
A growing body of evidence suggests that the nuclear fac-
tor of activated T lymphocytes (NFAT) is expressed in a vari-
ety of tissues in addition to lymphocytes (36). To date, NFAT
expression or function has been described in several types of
nonlymphoid cells, including mast cells (37), endothelial cells
(38), vascular smooth muscle cells (39), and neuronal cells
(40). The messenger RNAs of distinct NFAT isoforms are
expressed in a tissue-specific manner (41). Linette et al.
(41a) have documented a regulatory interaction between
Bcl-2 expression and NFAT activation. Thus, it is possible
that NFAT regulates the transcription of genes involved in
apoptosis and that antiapoptotic Bcl-2 family members act in
part by interfering with NFAT-induced gene transcription.
One candidate proapoptotic gene that is regulated by
NFAT is FasL. Transcription of the FasL gene is regulated
at least in part by an interaction of NFAT proteins with the
FasL promoter (42–44). Transcription mediated by NFAT
is regulated tightly in response to second messengers such as
calcium. Increased intracellular Ca
 
2
 
1
 
 stimulates calcineurin-
dependent dephosphorylation of cytoplasmic NFAT, lead-
ing to its nuclear translocation (45). T cell activation was
found to induce NFAT binding to the FasL enhancer (45).
Thus, it is possible that Bcl-2 mediates its antiapoptotic ef-
fects not only by forming heterodimers with proapoptotic
Bcl-2 family members but also through antagonism of NFAT
activation.
In this study, we examine the intracellular mechanisms
by which Bcl-2 inhibits apoptosis induced by microtubule-
damaging drugs (paclitaxel, vincristine, and vinblastine) in
Jurkat T lymphocytes and breast carcinoma cells. We dem-
onstrate that expression of FasL plays a significant role in
apoptosis induced by microtubule-damaging drugs. Upon
exposure to such drugs, FasL is rapidly expressed. Antibody
to FasL inhibits paclitaxel-induced apoptosis. In cells over-
expressing Bcl-2, FasL expression is blocked upon exposure
to low doses of paclitaxel. The mechanism by which Bcl-2
inhibits FasL expression is indirect; Bcl-2 binds to calcineurin
and inhibits its dephosphorylation and release of NFAT.
Thus, NFAT is unable to translocate to the nucleus and FasL
transcription does not occur. These results suggest a mech-
anism by which Bcl-2 acts to block drug- or activation-
induced apoptosis. Very high doses of paclitaxel can over-
come the inhibitory effects of Bcl-2 on NFAT nuclear
translocation. High doses of paclitaxel lead to Bcl-2 phos-
phorylation and dissociation from calcineurin, which allows
NFAT activation and FasL expression.
 
Materials and Methods
 
Reagents.
 
Paclitaxel, vincristine, vinblastine, ascomycin, and
6-diamidino-2-phenylindole (DAPI) were purchased from Sigma
 
Chemical Co. Secondary antibody (donkey anti–goat IgG) con-
jugated with Alexa-488 and 1,2-bis(
 
o
 
-aminophenoxy)ethane-
 
N
 
,
 
N
 
,
 
N
 
9
 
,
 
N
 
9
 
-tetraacetic acid tetra(acetoxymethyl)ester (BAPTA-AM)
were purchased from Molecular Probes, Inc. and Calbiochem
Corp., respectively. Antibodies against Bcl-2, 
 
b
 
-actin, Fas, and
FasL were purchased from Transduction Labs. FasL-neutralizing
antibody was purchased from PharMingen. Fas-blocking antibody
was purchased from Alexis. Antibody against NFAT was pur-
chased from Santa Cruz Biotechnology. Enhanced chemilumi-
nescent Western blot detection reagents were purchased from
Amersham Life Sciences, Inc. The chemiluminescent reporter
gene assay system for the combined detection of luciferase and
 
b
 
-galactosidase was purchased from Tropix, Inc. 
 
Cells and Culture Conditions.
 
Jurkat T cells and breast carci-
noma MDA-MB-231 and MCF-7 cells were obtained from
American Type Culture Collection. Cells were cultured in
RPMI 1640 tissue culture medium (BioWhittaker, Inc.) supple-
mented with 2 mM 
 
l
 
-glutamine, 10% fetal bovine serum, and 1%
penicillin–streptomycin mixture at 37
 
8
 
C with 5% CO
 
2
 
.
 
Transfection of Bcl-2 Genes.
 
Jurkat cells and MDA-MB-231
cells were transfected with wild-type Bcl-2 as described else-
where (25). The pSFFVneo-Bcl-2, pSFFVneo-Bcl-X
 
L
 
, and pSFFV
Neo plasmids were provided by Dr. Stanley Korsmeyer (Dana-
Farber Cancer Institute, Boston, MA). Jurkat cells (JT/mut CD95)
harboring a Fas mutant lacking the cytoplasmic domain were
provided by Dr. Gary A. Koretzky (University of Iowa, Iowa
City, IA) and described elsewhere (46). MDA-MB-231 cells were
also transfected with either pSFFVneo-
 
D
 
BH4 Bcl-2 or pSFFVneo-
 
D
 
loop Bcl-2 plasmid using lipofectine (GIBCO BRL). Trans-
duced cells were selected in RPMI 1640 containing 10% fetal bo-
vine serum and 1 mg/ml G418 (Geneticin; GIBCO BRL) for 1 mo.
Clones expressing the highest levels of Bcl-2 were used (data not
shown).
For transient transfection, lipofectine reagent was used to
transfect the plasmid as per manufacturer’s instructions (GIBCO
BRL). After transfection, the cells were incubated with complete
medium for one additional day. These cells were then used for
experiments.
 
Subcellular Fractionation.
 
Nuclear and cytosolic fractions were
prepared by resuspending cells in 0.8 ml ice cold buffer A (250 mM
sucrose, 20 mM Hepes, 10 mM KCl, 1.5 mM MgCl
 
2
 
, 1 mM
EDTA, 1 mM EGTA, 1 mM dithiothreitol, 17 
 
m
 
g/ml phenyl-
methylsulfonyl fluoride, 8 
 
m
 
g/ml aprotinin, and 2 
 
m
 
g/ml leupep-
tin, pH 7.4). Cells were passed through an ice cold cylindrical cell
homogenizer. Cell suspensions were pelleted at 750 
 
g
 
 for 20 min.
Cytoplasmic extract was separated from the pellet. This pellet was
resuspended in buffer A, homogenized, and spun at 10,000 
 
g
 
 for
25 min. The clear supernatant was considered nuclear extract.
 
Lysate Preparation.
 
For Western blot analysis, cells were lysed
in a buffer containing 10 mM Tris/HCl, pH 7.6; 150 mM NaCl;
0.5 mM EDTA; 1 mM EGTA; 1% SDS; 1 mM sodium ortho-
vanadate; and a mixture of protease inhibitors (1 mM phenyl-
methylsulfonyl fluoride, 1 
 
m
 
g/ml pepstatin A, and 2 
 
m
 
g/ml apro-
tinin). The lysates were then sonicated for 10 s and centrifuged
for 20 min at 1,200 
 
g
 
. The supernatants were used to perform
SDS-PAGE or stored at 
 
2
 
70
 
8
 
C.
 
Apoptosis.
 
For detection of apoptotic cells, the cells were first
washed twice with ice cold PBS and then fixed with 1% para-
formaldehyde for 30 min. The fixed cells were washed again with
PBS and stained with 1 
 
m
 
g/ml DAPI solution for 30 min. The
apoptotic cells were examined under a fluorescence microscope.
Fluorescent nuclei were screened for normal morphology (unal-
tered chromatin), and apoptotic nuclei comprising those with 
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fragmented (scattered) and condensed chromatin were counted.
Data are expressed as the percentage of apoptotic cells in total
counted cells.
 
Confocal Microscopy.
 
For the determination of NFAT translo-
cation by confocal microscope imaging (Axiovert 100; Carl Zeiss,
Inc.), cells from each group were seeded onto glass slides and
treated with paclitaxel for 48 h. At the end of the incubation pe-
riod, cells were fixed with 1% paraformaldehyde and 0.01% Tri-
ton X-100. Cells were incubated with propidium iodide (PI; 2
 
m
 
g/ml) containing RNAse for 1 h and subsequently with anti-
NFAT antibody (goat anti–human IgG; 2 
 
m
 
g/ml) for 1 h. After
incubation, cells were washed three times and restained with sec-
ondary antibody (donkey anti–goat IgG) conjugated with Alexa-
488 for 1 h. After mounting, cells were visualized for NFAT
translocation (Alexa; emission 488 nm and excitation 520 nm)
and nuclear fragmentation (PI; emission 540 nm and excitation
610 nm). The green and red colors represent cytoplasmic NFAT
and nuclear staining, respectively. The yellow color represents
NFAT translocated to the nucleus (red plus green) (see Fig. 4).
 
Results
 
FasL Is Involved in Paclitaxel-induced Apoptosis.
 
FasL induc-
tion has been demonstrated in activation-induced cell death
in T cells (47–51) and in the death of other cell types in-
duced by anticancer drugs (52), gamma irradiation (53),
and UV light (54). We investigated the possibility of the
involvement of the FasL/Fas pathway in paclitaxel-induced
apoptosis. Jurkat cells or MDA-MB-231 cells were stably
transfected with either pSSFV-Neo or pSSFV-Bcl-2 ex-
pression vector to assess the protective effects of Bcl-2 on
paclitaxel-induced apoptosis (Fig. 1, A and B). Treatment
of cells with paclitaxel resulted in induction of apoptosis in
a dose-dependent manner, and overexpression of Bcl-2 in-
hibited paclitaxel-induced apoptosis in Jurkat cells (Fig. 1 C).
The paclitaxel dose–response curve suggests a 10-fold in-
crease in resistance in cells overexpressing Bcl-2. Neutral-
ization of FasL by treatment of cells with anti-FasL anti-
body (NOK-2) significantly inhibited paclitaxel-induced
apoptosis in both JT/Neo and JT/Bcl-2 cells. Indeed, very
little tumor cell death could be documented in Bcl-2–over-
expressing Jurkat cells exposed to anti-FasL antibody. To
examine the role of Bcl-2 in paclitaxel-induced apoptosis,
we used MDA-MB-231 breast cancer cells, which do not
express endogenous Bcl-2 (Fig. 1 B). Overexpression of
Bcl-2 in MDA cells inhibited paclitaxel-induced apoptosis
by greater than two logs (Fig. 1 D). Neutralization of FasL
Figure 1. Bcl-2 inhibits paclitaxel-induced
apoptosis. (A) Jurkat cells were stably transfected
with either pSSFV-neo or pSFFV-Bcl-2 plas-
mid. (B) MDA-MB-231 cells were stably trans-
fected with either pSSFV-neo or pSFFV-Bcl-2
plasmid. (C) Jurkat cells (JT/Neo and JT/Bcl-2)
were treated with paclitaxel (0.001, 0.01, and
0.1 mM) with or without anti-FasL neutralizing
antibody (NOK-2; 1 mg/ml) for 48 h. Cells
were stained with DAPI and visualized under
fluorescence microscopy. Cells with fragmented
nuclei or condensed chromatin were counted as
apoptotic. Data (mean 6 SE of quadruplicate
determinations) represent one of three separate
experiments that gave similar results. (D) MDA/
MB/231 (MDA/Neo and MDA/Bcl-2) were
treated with paclitaxel (0.001, 0.01, and 0.1 mM)
with or without anti-FasL neutralizing antibody
(NOK-2; 1 mg/ml) for 48 h. Cells were stained
with DAPI and visualized under fluorescence microscopy. Cells with fragmented and condensed chromatin were counted as apoptotic. Data (mean 6 SE
of quadruplicate determinations) represent one of three separate experiments that gave similar results. (E) JT/Neo and JT/Bcl-2 cells were treated with
paclitaxel (0.001, 0.01, and 0.1 mM) with or without anti-Fas blocking antibody (1 mg/ml) for 48 h. Apoptotic nuclei were counted as described for D.
(F) JT/Neo and JT/mut CD95 cells were treated with paclitaxel (0.001, 0.01, and 0.1 mM) for 48 h. Apoptotic nuclei were counted as described for D. 
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by anti-FasL antibody (NOK-2) significantly inhibited
paclitaxel-induced apoptosis in MDA/Neo but had little
effect in MDA/Bcl-2 cells. Incubation of cells with Fas-
blocking antibody inhibited paclitaxel-induced apoptosis in
JT/Neo and JT/Bcl-2 cells. Similarly, overexpression of
mutant CD95/Fas (mutant receptors lacking intracellular
cytoplasmic domains) inhibited paclitaxel-induced apopto-
sis (Fig. 1 F). Taken together, these data demonstrate that
(a) paclitaxel-induced apoptosis can be inhibited by Bcl-2
and (b) the FasL/Fas pathway, at least in part, mediates pac-
litaxel-induced apoptosis.
 
Bcl-2 Blocks FasL Expression.
 
The induction of FasL
during activation- or drug-induced cell death has been re-
ported (47–52). As neutralization of FasL by anti-FasL anti-
body inhibited paclitaxel-induced apoptosis, we sought to
evaluate the expression of FasL in wild-type and Bcl-2–
overexpressing cells. Treatment of wild-type MDA cells with
paclitaxel, vincristine, or vinblastine induced FasL expres-
sion in a time-dependent manner (Fig. 2 A). Treatment of
breast cancer cells (MDA and MCF-7) with paclitaxel re-
sulted in induction of FasL in a dose-dependent manner
(Fig. 2 B). We have previously demonstrated that Bcl-2 in-
hibits apoptosis induced by microtubule-damaging drugs
(paclitaxel, vincristine, and vinblastine) (25); therefore, it
was of interest to examine whether Bcl-2 would also in-
hibit FasL expression. Treatment of MDA/Neo cells with
50 nM of paclitaxel or vincristine resulted in induction of
FasL; by contrast, the induction of FasL was blocked by
overexpression of Bcl-2 in MDA/Bcl-2 cells (Fig. 2 C).
JT/Neo cells expressed some FasL at baseline, and pacli-
taxel induced an increase in FasL expression. The expres-
sion of Bcl-2 in JT/Bcl-2 transfectants blocked both the
baseline expression and the induction of FasL by paclitaxel
(Fig. 2 D). Thus, Bcl-2 expression interferes with FasL ex-
pression.
 
Bcl-2 Blocks NFAT Translocation to the Nucleus.
 
The ac-
tivation of calcineurin, a serine phosphatase, is regulated by
calcium. Activated calcineurin functions to dephosphory-
late NFAT family members (45). Dephosphorylated NFAT
proteins then translocate to and enter the nucleus, where
they serve an essential role in regulating the expression of
many cytokine genes (55, 56). As Bcl-2 blocks paclitaxel-
induced FasL expression and apoptosis, we examined the
effects of Bcl-2 on NFAT translocation to the nucleus.
NFAT was localized to the cytoplasm in untreated (con-
trol) JT/Neo and JT/Bcl-2 (Fig. 3 A). When JT/Neo cells
were treated with paclitaxel, NFAT translocated to the
nucleus (Fig. 3 A). In contrast, overexpression of Bcl-2
blocked paclitaxel-induced NFAT translocation to the nu-
cleus (Fig. 3 A). Similarly, overexpression of Bcl-2 blocked
paclitaxel-induced NFAT translocation to the nucleus in
MDA/Bcl-2 cells (Fig. 3 B).
We confirmed paclitaxel-induced NFAT translocation by
confocal microscopy (Fig. 4). We next examined if Bcl-2
would block NFAT translocation to the nucleus in MDA
cells by immunocytochemistry. As seen in Fig. 4 B, NFAT
was localized to the cytoplasm in MDA/Neo and MDA/
Bcl-2 cells (Fig. 4, green). Treatment of MDA/Neo cells
with paclitaxel resulted in NFAT translocation to the nucleus
(Fig. 4, red plus green 
 
5 
 
yellow color) and apoptosis (frag-
mented nucleus stained with red color). As expected, overex-
pression of Bcl-2 blocked paclitaxel-induced NFAT translo-
cation to the nucleus and apoptosis in MDA cells (Fig. 4).
 
Bcl-2 Binds to Calcineurin but not NFAT.
 
The Bcl-2 in-
hibition of NFAT translocation to the nucleus is not direct
but rather involves calcineurin (57). It has been shown that
Figure 2. Bcl-2 inhibits paclitaxel-,
vincristine-, and vinblastine-induced
FasL expression. (A) MDA cells were
treated with 50 nM of paclitaxel,
vincristine, or vinblastine for either
24 or 48 h. At the end of incubation
period, cells were harvested and
lysed. Equal amounts of protein were
resolved on SDS-PAGE. FasL levels
were measured by Western blot anal-
ysis. The same blot was reprobed
with anti–b-actin antibody to check
if equal amounts of protein were
loaded in each lane. (B) MDA and
MCF-7 cells were treated with vari-
ous concentrations of paclitaxel for 48 h. FasL levels were detected by Western blot analysis. The blot was reprobed with anti–b-actin antibody to check
if equal amounts of protein were loaded in each lane. (C) MDA/Neo and MDA/Bcl-2 cells were treated with 50 nM of paclitaxel or vincristine for 48 h.
FasL levels were detected by Western blot analysis. The blot was reprobed with anti–b-actin antibody to check if equal amounts of protein were loaded
in each lane. (D) JT/Neo and JT/Bcl-2 cells were treated with paclitaxel (50 nM) for 48 h. FasL levels were detected by Western blot analysis. The blot
was reprobed with anti–b-actin antibody to check if equal amounts of protein were loaded in each lane. 
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Bcl-2 binds to calcineurin and thereby inhibits transloca-
tion of NFAT to the nucleus (57). As the FasL promoter
contains NFAT binding sites and NFAT participates in the
regulation of FasL expression in activated human T cells
(42), it was of interest to examine the intracellular mecha-
nism(s) by which Bcl-2 inhibited paclitaxel-induced FasL
expression. We have previously demonstrated that micro-
tubule-damaging drugs initiated a signaling cascade that
phosphorylated Bcl-2 in a time- and dose-dependent man-
ner (25). The JT/Neo and JT/Bcl-2 cells were treated with
50 nM of either paclitaxel or vincristine for 24 h, lysed, im-
munoprecipitated with anti-NFAT antibody, and blotted
Figure 3. Bcl-2 blocks NFAT
translocation to the nucleus. (A)
JT/Neo and JT/Bcl-2 cells were
either treated with paclitaxel (50
nM) or vehicle (control) for 48 h.
Cells were harvested, and cyto-
plasmic (C) and nuclear (N) frac-
tions were prepared as described
in Materials and Methods. Sam-
ples were resolved on SDS-PAGE
and immunoblotted with anti-
NFAT antibody. The same blot
was reprobed with anti–b-actin
antibody. (B) MDA/Neo and
MDA/Bcl-2 cells were either
treated with paclitaxel (50 nM) or
vehicle for 48 h. Cells were har-
vested and C and N fractions were
prepared as described in Materials
and Methods. Samples were re-
solved on SDS-PAGE and immu-
noblotted with anti-NFAT anti-
body. The same blot was reprobed
with anti–b-actin antibody.
Figure 4. Confocal microscopy showing
blockage of NFAT translocation by Bcl-2.
MDA/Neo and MDA/Bcl-2 cells were
treated with paclitaxel (50 nM) for 48 h. Cells
were fixed and stained with anti-NFAT anti-
body along with PI. Cells were washed and
restained with secondary antibody conjugated
with Alexa-488. Green and red represent
cytoplasmic NFAT and nuclear staining, re-
spectively. Yellow, NFAT translocated to the
nucleus. 
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with anti–Bcl-2 antibody (Fig. 5 A). These results indicated
that NFAT did not bind to Bcl-2 in either JT/Neo or
JT/Bcl-2 cells. When the NFAT immunoprecipitate was
followed by NFAT Western blot, similar amounts of
NFAT were immunoprecipitated (Fig. 5 A). Therefore,
the apparent lack of association of NFAT and Bcl-2 is not
related to inefficient NFAT immunoprecipitation. We next
examined the interaction between Bcl-2 and calcineurin in
paclitaxel- or vincristine-treated JT/Neo and JT/Bcl-2
cells. Cells were exposed to paclitaxel or vincristine for 48 h
and then lysed. Lysates were immunoprecipitated with an-
tibody to either Bcl-2 (Fig. 5 B) or calcineurin (Fig. 5 C),
and Western blots were performed with the antibody
not  used in the immunoprecipitation. As shown in Fig. 5 B
and C, Bcl-2 was able to bind calcineurin in untreated JT/
Neo and JT/Bcl-2 cells. When JT/Neo and JT/Bcl-2 cells
were treated with paclitaxel (50 nM) or vincristine (50
nM), less calcineurin was bound to Bcl-2 (Fig. 5, B and C).
These results suggest that Bcl-2 binds to calcineurin but not
to NFAT, and the fraction of Bcl-2 and calcineurin bound
to each other decreases upon exposure to the drugs. These
results suggest that the phosphorylation of Bcl-2 stimulated
by the drugs may also influence Bcl-2 binding to cal-
cineurin just as it affects Bcl-2–Bax interaction (25).
The immunosuppressants cyclosporin and FK506 inhibit
NFAT-dependent transcriptional events by binding cal-
cineurin and blocking its enzymatic activity, thus prevent-
ing the redistribution of NFAT to the nucleus (36). To
evaluate the involvement of active calcineurin in pacli-
taxel-induced apoptosis, cells were treated with the FK506
analogue ascomycin (Fig. 5 D). Paclitaxel induced apopto-
sis in both JT/Neo and MDA/Neo cells (Fig. 5 D). If Bcl-2
Figure 5. Bcl-2 binds to calcineurin but not NFAT. (A) JT/Neo and JT/Bcl-2 cells were treated with 50 nM of paclitaxel or vincristine for 48 h. The
cell lysates were prepared and immunoprecipitated with 10 mg of anti-NFAT antibody and 20 ml of protein A–Sepharose. The samples were resolved on
SDS-PAGE and immunoblotted with either anti–Bcl-2 antibody (top panel) or anti–NF-AT antibody (bottom panel). (B) JT/Neo and JT/Bcl-2 cells
were treated with 50 nM of paclitaxel or vincristine for 48 h. The cell lysates were prepared and immunoprecipitated with 10 mg of anti–Bcl-2 antibody
and 20 ml of protein A–Sepharose. The samples were resolved on SDS-PAGE and immunoblotted with anticalcineurin. (C) JT/Neo and JT/Bcl-2 cells
were treated with 50 nM of paclitaxel or vincristine for 48 h. The cell lysates were prepared and immunoprecipitated with 10 mg of anticalcineurin anti-
body and 20 ml of protein A–Sepharose. The samples were resolved on SDS-PAGE and immunoblotted with anti–Bcl-2 antibody. (D) Left, JT/Neo and
JT/Bcl-2 cells were treated with various concentrations of paclitaxel (0.001, 0.01, and 0.1 mM) with or without FK506 analogue ascomycin (10 mM) for
48 h to measure apoptosis. Cells were stained with DAPI and visualized under fluorescence microscopy. Cells with fragmented nuclei or condensed
chromatin were counted as apoptotic. Data (mean 6 SE of quadruplicate determinations) represent one of three separate experiments that gave similar
results. Right, MDA/Neo and MDA/Bcl-2 cells were treated with various concentrations of paclitaxel (0.001, 0.01, and 0.1 mM) with or without
FK506 analogue ascomycin (10 mM) for 48 h to measure apoptosis. Cells were stained with DAPI and visualized under fluorescence microscopy. Data
(mean 6 SE of quadruplicate determinations) represent one of three separate experiments that gave similar results. (E) JT/Neo and JT/Bcl-2 cells were
pretreated with [(Ca21)i] chelator BAPTA-AM (10 mM) for 45 min and then treated with paclitaxel (50 nM) for 48 h to measure apoptosis. Data (mean 6
SE of quadruplicate determinations) represent one of three separate experiments that gave similar results. 
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was acting to prevent calcineurin activation, its effects
should have been mimicked by the pharmacological cal-
cineurin inhibition of ascomycin. Overexpression of Bcl-2
inhibited paclitaxel-induced apoptosis in these cell lines. As
expected, treatment of cells with ascomycin inhibited pa-
clitaxel-induced apoptosis in neo- and Bcl-2–transfected
cells (Fig. 5 D). Ascomycin appears to inhibit apoptosis ad-
ditively in Bcl-2–expressing cells. It is possible that ascomy-
cin has additional effects unrelated to Bcl-2 binding of cal-
cineurin. These data confirm that inhibition of calcineurin
activation blocks paclitaxel-induced apoptosis.
Because a rise in intracellular free calcium levels [(Ca
 
2
 
1
 
)i]
is essential for calcineurin activation (56), we sought to ex-
amine the effects of chelating intracellular free calcium by
BAPTA-AM on paclitaxel-induced apoptosis (Fig. 5 E).
JT/Neo and JT/Bcl-2 cells were pretreated with 10 
 
m
 
M
BAPTA-AM for 45 min and then treated with paclitaxel (50
nM) for 48 h. Overexpression of Bcl-2 significantly inhibited
paclitaxel-induced apoptosis. Interestingly, chelation of in-
tracellular free calcium by BAPTA-AM inhibited paclitaxel-
induced apoptosis in JT/Neo and JT/Bcl-2 cells (Fig. 5 E).
That paclitaxel induces a rise in [(Ca
 
2
 
1
 
)i] has been described
by others (58) and confirmed by us (data not shown). These
data suggest that a rise in [(Ca
 
2
 
1
 
)i] is required for paclitaxel-
induced apoptosis. These results provide additional evidence
that paclitaxel-induced apoptosis involves a rise in [(Ca
 
2
 
1
 
)i],
leading to calcineurin activation, which in turn leads to
NFAT translocation and expression of FasL.
 
BH4 Domain of Bcl-2 Is Required for Interaction with Cal-
cineurin and Paclitaxel-induced FasL Expression and Apoptosis.
 
Thus, Bcl-2 blocked NFAT translocation by binding to
calcineurin but not directly to NFAT. The BH4 domain of
Bcl-2 has been demonstrated to mediate heterodimerization
with calcineurin. We wished to use this finding to verify that
the antiapoptotic effects of Bcl-2 were related to calcineurin
binding. To answer this question, MDA cells were trans-
fected with empty vector (MDA/Neo), wild-type Bcl-2
(MDA/Bcl-2), or 
 
D
 
BH4 Bcl-2 (Bcl-2 lacking 
 
D
 
BH4 do-
main, MDA/
 
D
 
BH4 Bcl-2) (Fig. 6 A). Cells were treated
with paclitaxel (50 nM) or left untreated (control) (Fig. 6 B).
Figure 6. Bcl-2 interacts with calcineurin through its BH4
domain in inhibiting paclitaxel-induced FasL expression and
apoptosis. (A) Western blot showing overexpressed wild-type
Bcl-2 and DBH4 Bcl-2 in MDA-MB-231 cells. (B) MDA/
Neo, MDA/DBH4 Bcl-2, and MDA/Bcl-2 cells were
treated with paclitaxel (50 nM) for 48 h. Cells were harvested
and lysed. FasL expression was detected by Western blot anal-
ysis. The same blot was reprobed with anti–b-actin antibody.
(C) MDA/Neo, MDA/Bcl-2, and MDA/DBH4 Bcl-2 cells
were treated with paclitaxel (50 nM) for 48 h. The cell lysates
were prepared and immunoprecipitated with 10 mg of anti-
calcineurin antibody and 20 ml of protein A–Sepharose. The
samples were resolved on SDS-PAGE and immunoblotted
with anti–Bcl-2 antibody. (D) MDA/Neo, MDA/Dloop
Bcl-2, and MDA/Bcl-2 cells were treated with paclitaxel
(200 nM) for 48 h. Top panel, cell lysates were run on SDS-
PAGE and immunoblotted with anti–Bcl-2 antibody. Bot-
tom panel, cell lysates were immunoprecipitated with anti–
Bcl-2 antibody, run on SDS-PAGE, and immunoblotted
with anticalcineurin antibody. (E) MDA/Neo, MDA/DBH4
Bcl-2, MDA/Dloop Bcl-2, and MDA/Bcl-2 cells were
treated with paclitaxel (0.001, 0.01, and 0.1 mM) for 48 h to measure apoptosis. Cells were stained with DAPI and visualized under fluorescence micros-
copy. Data (mean 6 SE of quadruplicate determinations) represent one of three separate experiments that gave similar results. 
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Fig. 6 B demonstrates that paclitaxel induced FasL expression
in MDA/Neo cells. Overexpression of wild-type Bcl-2
(MDA/Bcl-2), but not 
 
D
 
BH4 Bcl-2, inhibited paclitaxel-
induced FasL expression (Fig. 6 B). We next examined the
ability of 
 
D
 
BH4 Bcl-2 to bind with calcineurin in MDA cells.
MDA/neo, MDA/Bcl-2, and MDA/
 
DBH4 Bcl-2 cells were
treated with paclitaxel, and lysates were immunoprecipitated
with anticalcineurin antibody and immunoblotted with anti–
Bcl-2 antibody. Fig. 6 C demonstrates that wild-type Bcl-2
can be coimmunoprecipitated with calcineurin, and treat-
ment of cells with low doses of paclitaxel significantly inhib-
ited the Bcl-2–calcineurin interaction. As expected, DBH4
Bcl-2 was unable to heterodimerize with calcineurin.
As treatment of cells with high doses of paclitaxel causes
more complete Bcl-2 phosphorylation, we sought to ex-
amine if phosphorylated Bcl-2 can bind to calcineurin. We
and others have previously shown that the loop region of
Bcl-2 is an important target for regulatory phosphorylation
(59, 60). MDA/Neo, MDA/Dloop Bcl-2 (which can not
be phosphorylated), and MDA/Bcl-2 cells were treated
with 200 nM paclitaxel for 48 h (Fig. 6 D). Treatment of
MDA/Bcl-2 cells with high doses of paclitaxel causes phos-
phorylation of wild-type Bcl-2, whereas paclitaxel has no
effect on Dloop Bcl-2 (phosphorylation-deficient mutant)
(Fig. 6 D, top panel). In addition, phosphorylated Bcl-2
was unable to bind with calcineurin (Fig. 6 D, bottom
panel). By comparison, Dloop Bcl-2 was not phosphory-
lated by paclitaxel and formed heterodimers with cal-
cineurin. These data suggest that phosphorylation of Bcl-2
is essential for calcineurin to be released from the complex.
Because DBH4 Bcl-2 was not able to bind with cal-
cineurin, we sought to examine the effects of this mutant
on paclitaxel-induced apoptosis. Overexpression of wild-
type Bcl-2 in MDA cells significantly inhibited paclitaxel-
induced apoptosis, whereas overexpression of DBH4 Bcl-2
mutant had only a slight inhibiting effect (Fig. 6 E). In ad-
dition, overexpression of Dloop Bcl-2 completely inhibited
paclitaxel-induced apoptosis. Taken together, these data
suggest that the DBH4 domain of Bcl-2 plays a significant
role in heterodimerizing with calcineurin and inhibiting
paclitaxel-induced apoptosis, and the phosphorylation of
the Bcl-2 loop domain allosterically interferes with the
BH4–calcineurin interaction.
Bcl-2 Blocks Paclitaxel-induced FasL Promoter Activity. It has
been shown that the FasL promoter contains two NFAT
binding sites (42, 43). We next addressed the functional
importance of the two NFAT sites for paclitaxel-mediated
FasL expression by generating mutations at one or both
NFAT binding sites. Two FasL sites were also mutated in
the context of the full length, 486-bp FasL reporter so that
FasL expression in this system would not kill the cells. Jur-
kat cells were transfected with the wild-type reporter or
double mutant reporter constructs and then left untreated
or treated with paclitaxel. As shown in Fig. 7 A, treatment
of JT/Neo cells transfected with wild-type FasL reporter
resulted in a 10-fold increase in luciferase activity relative
to control cells. In contrast, the reporter containing muta-
tions in both NFAT sites exhibited no luciferase produc-
tion over control in JT/Neo cells (Fig. 7 A). Interestingly,
overexpression of the Bcl-2 gene in JT cells (JT/Bcl-2) in-
hibited wild-type FasL promoter activity in cells treated
with paclitaxel. As expected, low levels of luciferase activ-
ity were detected in cells transfected with the double
NFAT mutant reporter plasmid in JT/Bcl-2 cells (Fig. 7 A).
We next sought to examine the FasL promoter activation
in MDA-MB-231 cells that do not express endogenous Bcl-2
protein. Paclitaxel treatment of MDA/Neo cells transfected
with wild-type FasL reporter resulted in a 12-fold increase in
Figure 7. NFAT sites play important roles in FasL promoter activation. (A) Jurkat cells (JT/Neo and JT/Bcl-2) were transfected with 70 mg of the wild-
type 486-bp FasL reporter (FasL-486) or a reporter containing mutations in both the distal and proximal NFAT sites (double mutant). Transfectants were
left untreated (control) or treated with paclitaxel (100 nM) for 48 h. Cells were lysed and assayed for luciferase activity. Data are expressed as arbitrary lu-
ciferase light units and are representative of four independent experiments. Error bars, SE of triplicate samples. (B) MDA/Neo and MDA/Bcl-2 cells were
transfected with 70 mg of the wild-type 486-bp FasL reporter (FasL-486) or a reporter containing mutations in both the distal and proximal NFAT sites
(double mutant). Transfectants were left untreated (control) or treated with paclitaxel (100 nM) for 48 h. Cells were lysed and assayed for luciferase activity.
Data are expressed as arbitrary luciferase light units and are representative of four independent experiments. Error bars, SE of triplicate samples.261 Srivastava et al.
luciferase activity relative to control cells. In contrast, overex-
pression of Bcl-2 blocked FasL promoter activation in pacli-
taxel-treated MDA/Bcl-2 cells (Fig. 7 B). By comparison,
low levels of luciferase activity were detected in cells trans-
fected with double NFAT mutant reporter plasmid in MDA/
Bcl-2 cells (Fig. 7 A). Collectively, these results indicate that
Bcl-2 blocked FasL transcription by inhibiting NFAT activity.
Discussion
Involvement of FasL in Apoptosis. Activation of T cells
results in expression of FasL and induction of apoptosis. In
comparison to activation-induced FasL expression in T
cells, FasL is constitutively expressed in other selected cell
types. The identification of FasL expression on cells in im-
mune privileged sites, such as testis (9) and the anterior
chamber of the eye (10), has suggested that FasL may be
important in tolerance induction and immunosuppression.
Indeed, inflammatory cells in the anterior chamber of the
eye undergo Fas-mediated apoptosis and show a systemic
tolerance to herpes simplex virus (HSV-1) infection (10).
In addition to immune cells, expression of FasL on human
tumors, including colon (61), hepatocellular carcinoma (62,
63), melanoma (12), and lung carcinoma (13) has been
demonstrated; this expression on cancer cells may be in-
volved in induction of apoptosis in Fas-expressing T cells.
Here we have shown that paclitaxel-induced apoptosis in
lymphoid and breast tumor cells is mediated at least in part
by increased expression of FasL. As Fas is constitutively ex-
pressed in most tumors cells, induction of FasL would be an
amplification signal for tumor cell apoptosis. FasL-neutraliz-
ing antibody nearly completely abrogates apoptosis induced
by microtubule poisons such as paclitaxel and vinblastine.
Recent studies have suggested that environmental stress
mediated by exposure to gamma irradiation (53), UV light
(54), and anticancer drugs such as etoposide or doxorubicin
(52) induces upregulation of Fas receptors and ligands, re-
sulting in autocrine or paracrine cell death. However, the
level of Fas expression is only one of the factors regulating
the susceptibility to Fas-mediated apoptosis (64). Exposure
to radiation, anticancer drugs, or other forms of stress may
lead to apoptosis, not only by increasing surface expression
of Fas, but also by affecting intracellular signaling molecules
activated upon Fas ligation. Indeed, numerous drug-resis-
tant cell lines were also found to be resistant to Fas-medi-
ated apoptosis (65). These findings support the hypothesis
that apoptosis mediated by both chemotherapeutic agents
and physiologic stimuli such as Fas ligation may share com-
mon downstream effector molecules.
Bcl-2 Inhibits NFAT Translocation to the Nucleus by Binding
to Calcineurin but not NFAT. The expression of FasL is in-
hibited by immunosuppressive agents CsA and FK506 (47,
50, 66, 67), suggesting that the transcription factor NFAT is
involved in FasL induction. Our data demonstrate that the
FK506 analogue ascomycin inhibits paclitaxel-induced FasL
expression and blocks apoptosis. These data suggest that the
calcineurin–NFAT pathway is involved in the control of FasL
expression and consequent paclitaxel-induced apoptosis.
Current evidence indicates that both nuclear import and
export of NFAT can be regulated dynamically (68, 69). In
T cells, relatively profound and sustained cytosolic Ca21
transients, such as those that occur after antigen receptor
engagement, appear to be necessary to activate calcineurin
and counterbalance the effects of processes that effect nu-
clear export of NFAT (70). It has recently been suggested
that the Ca21 signals of shorter duration elicited by activa-
tion of the Gaq receptors may preferentially activate the
putative negative regulatory processes (71), whereas acti-
vation of calcineurin, dephosphorylation of NFAT, and its
subsequent nuclear import require Ca21 transients of longer
duration. Recent studies have provided evidence that a nu-
clear kinase activity is involved in rephosphorylating NFAT
and exporting it to the cytosol as a means for terminating
its transcriptional activity (72). Although protein kinase A
and glycogen synthase kinase 3 have been implicated as the
major NFAT kinases in Jurkat T cells, calmodulin-depen-
dent kinases appear to have some NFAT nuclear export ac-
tivity as well as a heterotopic expression system (70).
We have shown that NFAT regulates the induction of
FasL upon paclitaxel treatment in Jurkat T cells and breast
cancer cells. It has been demonstrated that the FasL promoter
contains two NFAT binding sites (bp 2263 to 2283 rela-
tive to the FasL translation). Furthermore, the ability of a
mutation in this NFAT site (within the context of a 486-bp
FasL reporter) to prevent reporter activity in lymphocytes
illustrates that this response element is critical for the regu-
lated expression of FasL in our studies. In addition to the
observation that CsA inhibits expression of FasL (47, 50,
67) in lymphocytes and that NFAT-deficient mice do not
inducibly express FasL (73), these results strongly suggest
that NFAT transcription factors are critical for the regula-
tion of FasL expression in lymphocytes and breast carcinoma.
The induction of FasL reporter expression is blocked by
overexpression of Bcl-2.
The comparison of the NFAT binding region of the
FasL promoter with IL-2 and TNF-a promoters provides
some insight into the regulation of these genes. AP-1 (acti-
vator protein 1) binding sequences are adjacent to NFAT
sites in the IL-2 promoter (74), whereas the NFAT sites
from the FasL promoter do not include any surrounding
predicted AP-1 binding sequences. In contrast, the se-
quence of the FasL promoter NFAT binding site is similar
to that of a previously reported NFAT site within the
TNF-a promoter (75). Because of the structural and func-
tional similarities between TNF-a and FasL, it is intriguing
to speculate that the conserved NFAT regulatory sequences
within the promoters of these genes may have arisen from
a common ancestral apoptosis-inducing gene.
As FasL plays an important role in control of lymphocyte
apoptosis, and, according to our data, drug-induced apop-
tosis, we have examined the intracellular mechanism of FasL
induction in human T cells and breast cancer cells. The
mechanism by which Bcl-2 inhibits drug-induced FasL ex-
pression and apoptosis is not known. We have demonstrated
that Bcl-2 inhibits paclitaxel-induced NFAT translocation
to the nucleus through interactions with calcineurin. In-262 Inhibition of Fas Ligand Transcription by Bcl-2
deed, Bcl-2 does not bind to NFAT directly, as has also
been reported by others (57). The BH4 domain of Bcl-2
binds to calcineurin and thereby inhibits the translocation
of NFAT. Calcium-dependent phosphorylation of calci-
neurin is essential for activation of NFAT and subsequent
translocation to the nucleus.
The inhibition of paclitaxel-induced NFAT translocation
and apoptosis by Bcl-2 may be one of the mechanisms by
which Bcl-2 regulates apoptosis. We have previously shown
that microtubule-damaging drugs (paclitaxel, vincristine, and
vinblastine) induced Bcl-2 phosphorylation and apoptosis.
Indeed, phosphorylated Bcl-2 loses its antiapoptotic func-
tion and is unable to heterodimerize with the proapop-
totic partner Bax. This free Bax itself can induce apoptosis.
Therefore, phosphorylation of Bcl-2 may result in at least
two events: (a) release of Bax and (b) failure to hold on to
or sequester calcineurin.
Model: Inhibition of Paclitaxel-induced Apoptosis by Bcl-2.
Collectively, these data support a model in which micro-
tubule-damaging drugs such as paclitaxel stimulate an in-
crease in intracellular free Ca21 that activates calcineurin,
which results in NFAT nuclear translocation, FasL expres-
sion, and apoptosis (Fig. 8 A). Apoptosis can be blocked ei-
ther by treatment of cells with anti-FasL antibody (Fig. 1)
or by overexpression of Bcl-2. Bcl-2 sequesters calcineurin,
which results in blockage of NFAT nuclear translocation,
FasL expression, and apoptosis (Fig. 8 B). All of the phos-
phorylation sites of Bcl-2 are located within the loop re-
gion (amino acid 32–80). The loop region deletion mutant
Bcl-2 (Dloop Bcl-2) cannot be phosphorylated and does
not release calcineurin from the complex after paclitaxel
exposure, and it becomes hyperfunctional in inhibiting
drug-induced apoptosis. The inhibition of FasL transloca-
tion by Bcl-2 can be overcome by treatment of cells with
high doses of paclitaxel (.100 nM) (Fig. 8 C). Treatment
of cells with high doses of paclitaxel results in inactivation
of Bcl-2 through phosphorylation. Phosphorylated Bcl-2
cannot bind calcineurin, and NFAT activation and FasL
expression can occur after Bcl-2 phosphorylation.
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